Clinical trials: Metastatic Castrate Resistant Prostate Cancer
- Condition Metastatic Castrate Resistant Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
Prostate Cancer
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy.
- Trial name
- NCT04221542
- Testing
- AMG 509, Abiraterone, Enzalutamide
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 479 people
- Sponsor
- Amgen
CRPC, Prostate Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT01812746
- Testing
- BIND-014
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- BIND Therapeutics
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
- Trial name
- NCT00048659
- Testing
- YM598
- Where
- 53 sites in United States, Australia and 8 more
- Sponsor
- Astellas Pharma Inc
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer
Study of AZD0754 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
- Trial name
- APOLLO (NCT06267729)
- Testing
- AZD0754, AZD2287
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent…
- Trial name
- NCT06104449
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Advanced Solid Tumor, Ovarian Cancer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary
- Trial name
- NCT05252390
- Testing
- NUV-868, Olaparib, Enzalutamide
- Where
- 22 sites in United States, Australia
- Volunteers
- 82 people
- Sponsor
- Nuvation Bio Inc.
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT03741712
- Testing
- SHR3680, SHR2554
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
- Trial name
- NCT06241846
- Testing
- YL201 for Injection
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration Resistant Prostate Cancer (mCRPC)
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other…
- Trial name
- EPIX (NCT04516161)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,180 people
- Sponsor
- Bayer
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
The purpose of this registry is to document the characteristics and management of patients with metastatic castrate resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used.
- Trial name
- NCT02236637
- Where
- 146 sites in Austria, Belgium and 13 more
- Volunteers
- 3,050 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Castration-Resistant Prostatic Cancer, Metastatic Disease
Safety and Targeting of Anti-hk2 Antibody in mCRPC
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo…
- Trial name
- NCT04116164
- Testing
- 111In-DOTA-h11B6
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SpectronRX
Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
This is a Phase 1b/Phase 2a, open-label, multicenter study to determine the safety, tolerability, recommended Phase 2 dose (RP2D), efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) properties of idronoxil when rectally…
- Trial name
- NCT04957290
- Testing
- NOX66, EBRT
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Noxopharm Limited
Prostatic Neoplasms
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC)…
- Trial name
- NCT03523442
- Testing
- Apalutamide
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC